Eli Lilly and Company
Pharmaceuticals
LLY
$ 292 0.28
Share price
$ 277 bn
Market Cap
$ 277 bn
Enterprise Value
Carbon footprint
Primary Climate Goal
Eli Lilly and Company aims to achieve net zero for Scope 1 + 2 by 2030
This target has not been verified as science based according to SBTi
GHG emissions and Carbon intensity
Eli Lilly and Company reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 710 Kt (-78 /-9.9% y-o-y). Also positively, carbon intensity plunged to 29 t (-6.4 /-18.1% y-o-y).
Eli Lilly and Company's Scope 3 emissions plummeted to 176 Kt (
The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -71 Kt per annum over the period of FY2021 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.
Copyright © 2022 Exerica. All rights reserved.